After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes.

Saved in:

Bibliographic Details
Title:	After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes.
Authors:	Colhoun, Helen
Source:	Lancet. 11/26/2005, Vol. 366 Issue 9500, p1829-1831. 3p.
Subjects:	Type 2 diabetes, Diabetes, Antilipemic agents, Endocrine diseases, Coronary disease, Lancet, The (Periodical), Medical research
Abstract:	The article discusses a FIELD investigators report published in the November 26, 2005 edition of "The Lancet," focusing on the efficacy and safety of 200 mg fenofibrate in preventing CVD in patients with type 2 diabetes. The author reports that there was a non-significant 11% reduction in the primary endpoint of coronary heart disease events, and a significant 11% reduction in total CVD events. The methods used to conduct the study are discusses, as are the participants in the study. It is the author's view that the FIELD is an important study because it allows medical professionals to ask whether fibrates could reasonably replace statins as first choice for primary or secondary prevention of CVD.
Database:	Psychology and Behavioral Sciences Collection

Description
Abstract:	The article discusses a FIELD investigators report published in the November 26, 2005 edition of "The Lancet," focusing on the efficacy and safety of 200 mg fenofibrate in preventing CVD in patients with type 2 diabetes. The author reports that there was a non-significant 11% reduction in the primary endpoint of coronary heart disease events, and a significant 11% reduction in total CVD events. The methods used to conduct the study are discusses, as are the participants in the study. It is the author's view that the FIELD is an important study because it allows medical professionals to ask whether fibrates could reasonably replace statins as first choice for primary or secondary prevention of CVD.
ISSN:	01406736
DOI:	10.1016/S0140-6736(05)67668-4